Search

A new study led by MSK investigators reveals how some cancer cells become resistant to targeted treatment and suggests what might be done to stop that from happening.

Chemotherapy is among the most commonly prescribed, and commonly misunderstood, cancer treatments. It’s time to revise what you thought you knew.

Discover how cyclist Stacia Smart turned her grief into purpose after her boyfriend died of a brain tumor.

It’s not every day that scientists discover a new part of the cell. Two biologists from the Sloan Kettering Institute just did.

Learn how a novel drug is showing promise against lung and pancreatic cancer in early clinical trials by targeting the KRAS G12D mutation with a KRAS degrader.

New research from Memorial Sloan Kettering highlighted in advance of the 50th Annual Meeting of the American Society of Clinical Oncology demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of advanced pigmented villonodular synovitis, a rare and debilitating joint disease.

As America commemorates the 50th anniversary of the “War on Cancer,” MSK addresses the question “Where do we go from here?”

There are new, FDA-authorized treatment options for people facing esophageal and gastric (stomach) cancer, thanks to clinical trials at Memorial Sloan Kettering that combined immunotherapy with standard treatments.